<DOC>
	<DOCNO>NCT00209937</DOCNO>
	<brief_summary>To evaluate efficacy safety tolerability gaboxadol primary insomnia</brief_summary>
	<brief_title>A Prospective Active-Reference Study Gaboxadol Primary Insomnia</brief_title>
	<detailed_description>To compare hypnotic efficacy safety different dose level gaboxadol placebo non-elderly patient primary insomnia two week treatment</detailed_description>
	<mesh_term>Sleep Initiation Maintenance Disorders</mesh_term>
	<mesh_term>Gaboxadol</mesh_term>
	<criteria>diagnosis Primary insomnia</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>March 2007</verification_date>
	<keyword>Primary insomnia</keyword>
</DOC>